| Literature DB >> 21626032 |
Isabel Poschke1, Dimitrios Mougiakakos, Rolf Kiessling.
Abstract
The field of tumor immunology has made great progress in understanding tumor immune interactions. As a consequence a number of immuno-therapeutic approaches have been successfully introduced into the clinic and a large number of promising therapeutic strategies are investigated in ongoing clinical trials. Evaluation of anti-tumor immunity in such trials as well as in animal models has shown that tumor escape from immune recognition and tumor-mediated suppression of anti-tumor immunity can pose a significant obstacle to successful cancer therapy. Here, we review mechanisms of tumor immune escape and immune-subversion with a focus on the research interests in our laboratory: loss of MHC class I on tumor cells, increased oxidative stress, recruitment of myeloid-derived suppressor cells, and regulatory T cells.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21626032 DOI: 10.1007/s00262-011-1012-8
Source DB: PubMed Journal: Cancer Immunol Immunother ISSN: 0340-7004 Impact factor: 6.968